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Charles A. Specht,a Chrono K. Lee,a Haibin Huang,a Donald J. Tipper,b Zu T. Shen,c* Jennifer K. Lodge,d John Leszyk,e
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ABSTRACT A vaccine capable of protecting at-risk persons against infections due to Cryptococcus neoformans and Cryptococ-
cus gattii could reduce the substantial global burden of human cryptococcosis. Vaccine development has been hampered
though, by lack of knowledge as to which antigens are immunoprotective and the need for an effective vaccine delivery system.
Wemade alkaline extracts frommutant cryptococcal strains that lacked capsule or chitosan. The extracts were then packaged
into glucan particles (GPs), which are purified Saccharomyces cerevisiae cell walls composed primarily of -1,3-glucans. Subcu-
taneous vaccination with the GP-based vaccines provided significant protection against subsequent pulmonary infection with
highly virulent strains of C. neoformans and C. gattii. The alkaline extract derived from the acapsular strain was analyzed by
liquid chromatography tandemmass spectrometry (LC-MS/MS), and the most abundant proteins were identified. Separation of
the alkaline extract by size exclusion chromatography revealed fractions that conferred protection when loaded in GP-based vac-
cines. Robust Th1- and Th17-biased CD4 T cell recall responses were observed in the lungs of vaccinated and infected mice.
Thus, our preclinical studies have indicated promising cryptococcal vaccine candidates in alkaline extracts delivered in GPs. On-
going studies are directed at identifying the individual components of the extracts that confer protection and thus would be
promising candidates for a human vaccine.
IMPORTANCE The encapsulated yeast Cryptococcus neoformans and its closely related sister species, Cryptococcus gattii, are ma-
jor causes of morbidity andmortality, particularly in immunocompromised persons. This study reports on the preclinical devel-
opment of vaccines to protect at-risk populations from cryptococcosis. Antigens were extracted from Cryptococcus by treatment
with an alkaline solution. The extracted antigens were then packaged into glucan particles, which are hollow yeast cell walls com-
posed mainly of-glucans. The glucan particle-based vaccines elicited robust T cell immune responses and protected mice from
otherwise-lethal challenge with virulent strains of C. neoformans and C. gattii. The technology used for antigen extraction and
subsequent loading into the glucan particle delivery system is relatively simple and can be applied to vaccine development
against other pathogens.
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Virtually all cases of cryptococcosis are caused by Cryptococcusneoformans and the closely related species Cryptococcus gattii
(1, 2). C. neoformans and C. gattii are unique among medically
important fungi in that their major virulence factor is a capsule
composed primarily of glucuronoxylomannan (GXM) (3).
C. neoformans has a worldwide distribution, with human expo-
sure mainly occurring following inhalation of airborne organ-
isms. The global burden of cryptococcal meningitis in people with
AIDShas been estimated to be about 1million cases annually, with
a 60% mortality rate (4). Other immunosuppressed persons are
also at high risk, e.g., about 1 to 5% of solid organ transplant
recipients will develop cryptococcosis in their lifetimes (5).C. gat-
tii has historically been found in tropical and subtropical regions,
but hypervirulent strains have emerged on Vancouver Island,
Canada, and spread to the mainland, including the U.S. Pacific
Northwest (2, 6, 7). This habitat expansion has been theorized to
be due to climate change, raising concerns about further spread
(2, 8).
Despite the prevalence of cryptococcosis, there are no licensed
cryptococcal vaccines. Populations that could be targeted for vac-
cination include the following: (i) HIV-infected persons; (ii) per-
sons on medications which suppress T cells (particularly trans-
plant recipients); (iii) persons living in regions where C. gattii is
endemic; and (iv) persons with other high-risk diseases (e.g., sar-
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coidosis, lymphoma). Preclinical approaches to developing cryp-
tococcal vaccines have included immunization with protein-
GXM conjugates and peptide mimetics of GXM designed to elicit
antibody-mediated protection, as well as live and killed C. neofor-
mans strains (9–15). Other work has focused on the identification
of C. neoformans antigens that stimulate protective T cell re-
sponses. Much of this effort has focused onmannoproteins (MPs;
defined by their affinity for the mannose-binding lectin conca-
navalin A), which comprise a major antigenic fraction recognized
by T cells of mice and humans (16–18). The extensive mannosy-
lation ofMPs promotes uptake bymannose receptors on antigen-
presenting cells, which leads to adaptive immune responses (18–
21). However, vaccination with MPs admixed via the Ribi
adjuvant system (Abcam; which biases toward antibody re-
sponses) resulted in only modestly prolonged survival of C. neo-
formans-challenged mice (22). Moreover, vaccination with the
flowthrough fraction (defined as the antigens which did not bind
concanavalin A) also elicited modest protection. These data sug-
gest Cryptococcus vaccines designed to elicit protective T cell re-
sponses will require novel adjuvant and/or antigen compositions
in order to be successful.
Glucan particles (GPs) are highly purified, hollow, porous cell
wall shells manufactured by treating baker’s yeast (Saccharomy-
ces cerevisiae) with a series of alkaline, acid, and solvent extractions
(23–26). They are composed primarily of -1,3-glucan and are
devoid of proteins, lipids, andmannans.GPs are recognized by the
C-type lectin receptor Dectin-1, but also potently activate the al-
ternative pathway of complement (27, 28). In vivo, phagocytosis of
GPs is mediated by both complement receptors and Dectin-1
(29). GPs stimulate dendritic cells (DCs) to produce cytokines
associated with beneficial responses in vaccine models of protec-
tion (27). Importantly, polymer-complexed “payload” classes, in-
cluding proteins, small interfering RNA, DNA, and other small
molecules can be constructed within the hollowGPs, enabling the
cellular delivery of a wide variety of “payload” classes (23, 29–31).
Immunization of mice with GPs loaded with the model antigen
ovalbumin (OVA) results in potent and long-lasting antigen-
specific antibody and Th1/Th17-biased CD4 T cell responses,
even when using low doses of ovalbumin (23, 24).Moreover, ben-
eficial effects have been noted in experimental Ascomycota infec-
tions, including aspergillosis and coccidioidomycosis, following
vaccination of mice with fungal antigens in GPs (32, 33).
In the present study, we tested GPs as a vaccine delivery system
in murine models of cryptococcosis. As a source of antigens, the
GPs were loaded with soluble extracts obtained following mild
alkali treatment of cryptococcal strains. Mice that received ex-
tracts encased in GPsmounted antigen-specific CD4T cell recall
responses and were protected from subsequent lethal challenges
with C. neoformans and C. gattii.
RESULTS
Establishment of a C57BL/6mousemodel of cryptococcosis us-
ingC. neoformans strains derived fromH99 for vaccination and
challenge studies.A robust test of vaccine efficacy should demon-
strate protection of genetically susceptible hosts against challenge
with fully virulent pathogens. Therefore, when setting up our
cryptococcosis vaccinemodel, we chose to use theC57BL/6mouse
strain. This inbred strain has been extensively studied and has
been found to be particularly sensitive to infection by C. neofor-
mans (34, 35). C. neoformans Kn99 (here referred to as Kn99), a
hypervirulentmating-type strainwhich has been backcrossed 10
times to the well-studied clinical H99 strain (36), was selected for
the fungal challenges. To mimic natural infection, mice were in-
oculated intranasally under conditions promoting pulmonary as-
piration. As expected, C57BL/6 mice rapidly succumbed to intra-
nasal challenge doses of 103, 104, or 105 CFU Kn99 (Fig. 1A).
Median survival was extended by only a few days as the challenge
dose decreased. Even at the lowest challenge dose of 103 CFU, all
mice succumbed. For the subsequent vaccination studies, we used
105 CFU of Kn99 as the challenge dose.
Acapsular strains of C. neoformans are not only hypovirulent,
but also, when used as a live vaccine delivered subcutaneously,
they confer some protection against subsequent challenge with
fully encapsulated cryptococcal isolates (11). Consistent with
these findings,mice that received a subcutaneous vaccinationwith
live acapsular strain cap59 were partially protected from lethal
challengewithKn99 (Fig. 1B). Protection, albeit not as robust, was
also observed following vaccination with the live cda1 cda2
cda3 mutant strain (cda123 strain), an attenuated strain which
lacks cell wall chitosan (37–39). Strains cap59 and cda123 were
derived from wild-type strains H99 and Kn99, respectively (39,
40). Two weeks after fungal challenge, CFU counts in lungs were
significantly lower in the mice vaccinated with cap59 (Fig. 1C). In
contrast, at this time point fewmice had CFU in their brain tissue
(Fig. 1D).
Extraction of antigens from strains cap59 and cda123. The
vaccination studies with the live attenuated strains suggested that
these strains contained antigens that conferred protection. Amild
alkaline extraction technique, described in Materials and Meth-
ods, was developed to test whether protective antigens could be
recovered from the two mutant fungal strains for use as subunit
vaccines. Typically, a purified extract from 500 ml of culture con-
tained about 7.5 mg of protein. The endotoxin concentration
ranged from 0.5 to 18 endotoxin units (EU)/mg of protein in four
lots of the cap59 extract and 0.02 to 0.05 EU/mg of protein in two
extracts of cda123. The alkaline extracts contained numerous pro-
tein and carbohydrate bands when resolved by SDS-PAGE
(Fig. 2). Despite being derived from the same genetic background,
many of the bands were unique to only one of the strains. As
expected, the carbohydrate stain periodic acid-Schiff (PAS) dem-
onstrated that the extracts from the cda123 strain, but not the
cap59 strain, had a very-high-molecular mass band consistent
with the GXM component of the capsule.
The cap59 extracts were then subjected to LC-MS/MS. Pro-
teins were identified using the C. neoformans var. grubii database
and analyzed for their relative abundance. Phosphatidylglycerol
transfer protein was the most abundant protein, followed closely
by superoxide dismutase. Proteins whose relative abundance was
at least 5% that of phosphatidylglycerol transfer protein are listed
in Table 1. Importantly, a whole transcriptome shotgun sequenc-
ing (RNA-Seq)-based analysis of C. neoformans isolates obtained
from the cerebrospinal fluid of two patients with cryptococcal
meningitis (41) showed mRNA encoding all 23 proteins. Several
had high RNA-Seq read numbers, suggesting that these extracted
proteins are likely produced during infection.
Protection of mice vaccinated with cap59 and cda123 strain
extracts in GPs. Soluble alkaline extracts from cap59 and cda123
were packaged into GPs (here designated GP-cap59 and GP-
cda123). Mice were then vaccinated subcutaneously (three times,
at 2-week intervals, with 10 g of protein/dose) and challenged
Specht et al.
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with C. neoformans Kn99. Control mice that were left unvacci-
nated or were vaccinated with mouse serum albumin in GPs (GP-
MSA) all died within 27 days (Fig. 3A). However, the mice that
received GP-cap59 or GP-cap123 vaccination had significantly
prolonged survival; 60% of the vaccinated mice were still alive
when the experiment was terminated at 50 days. CFU counts from
lungs of the euthanized survivors were determined (Fig. 3B).
While CFU in most mice were below the limit of detection, lungs
from two mice had CFU greater than 106.
Chitin deacetylases (CDAs), particularly CDA2, have been
shown to be targets of the T cell response (42, 43). Moreover,
CDA2 was among the top antigens identified in the cap59 extracts
(Table 1). Therefore, to avoid losing potentially protective CDA
antigens and to circumvent potential inhibitory effects of GXM
(44), we elected to focus on the alkaline extracts from the cap59
strain. To determine the reproducibility of the vaccination system,
five distinct lots of GP-cap59 were made and separately tested.
Overall, each lot behaved similarly and, taken in aggregate, signif-
icant protection compared to GP-MSA controls was seen (Fig. 3C
andD). As in Fig. 3B, within the 50-day period following infection
with 105 CFU of Kn99, the median fungal load in the lungs of
survivors was reduced more than 100-fold (Fig. 3D); in several
mice, CFU were below the detection limit.
Ex vivoCD4 T cell responses following vaccination. In pre-
vious studies, we demonstrated that vaccination of mice with GPs
containing the model antigen ovalbumin (GP-OVA) induced po-
tent CD4 T cell responses, even when relatively low doses of
antigen were used as ex vivo stimuli (23, 24). This raised the pos-
sibility that ex vivo assays could be used to determine the antigen
components of cap59 responsible for T cell stimulation. CD4 T
cells, purified frommice that had been vaccinated with GP-cap59,
were stimulated with a range of concentrations of GP-cap59, and
FIG 1 Protection of C57BL/6 mice by vaccination with live cap59 and cda123 strains. (A) Naive C57BL/6 mice were inoculated intranasally with 103, 104, or
105 CFU of strain Kn99, and their survival was monitored. P 0.01 comparing animals that received 104 versus 103 or 105 CFU; P 0.0001 comparing animals
that received 103 versus 105 CFU. (B) An intranasal challenge with 105 CFU of Kn99 was used to monitor survival of mice that were vaccinated three times with
106CFUof liveC. neoformans strain cap59 or cda123. Survival curves are from two independent experiments, eachwith 5mice per group.Unvaccinated (NoVac)
mice served as controls. P 0.01 and P 0.0001 comparingNoVac animals versus animals vaccinated with cda123 or cap59, respectively. (C andD) CFU in the
lungs and brains of unvaccinated and vaccinatedmice 2 weeks postchallenge with 105 CFU of Kn99. Mice with no CFUwere assigned a value of 100 CFU, which
was the lower limit of detection of the assay. P 0.05 comparing lung CFU of unvaccinated versus cap59-vaccinated mice.
FIG 2 SDS-PAGE results for cap59 and cda123 extracts. Alkaline extracts
were prepared from C. neoformans strains cap59 and cda123. Each lane was
loaded with 50g of protein. The left lanes showmolecular mass size markers
(in kilodaltons). (A) Gels were stained for protein with Coomassie blue. (B)
Replicate lanes from the same gel were stained for carbohydrate with PAS. The
arrow identifies the region expected for GXM.
GP-Based Cryptococcal Vaccines
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lymphoproliferation (LP) was determined. Significant ex vivo re-
sponses were seen at concentrations of cap59 as low as 1 ng/well
(Fig. 4).
Fractions of cap59 extracts responsible for T cell stimulation
and protection. cap59 extracts were separated by size exclusion
chromatography into 1-ml fractions. Each fraction was then as-
sayed for protein and carbohydrate concentrations as well as the
capacity to stimulate ex vivo CD4 T cell lymphoproliferation
(Fig. 5A). Lymphoproliferative responses were strongest with the
higher-molecular-size fractions. Moreover, lymphoproliferative
responses correlated with carbohydrate concentrations to a much
greater extent than to protein concentrations.
We next sought to determine which fractions were responsible
for protection inmice. Due to the small amount of antigen in each
fraction, we combined fractions into pools of 4 fractions and con-
centrated them30-fold. Thesewere then loaded intoGPs and used
to vaccinate mice. Only five mice per group could be studied, on
account of the limited amount ofmaterial obtained. Nevertheless,
the results were striking, with 4/5 mice in the group containing
pooled fractions 8 to 11 surviving (Fig. 5B). In contrast, except for
one survivor in the fractions 4 to 7 group, all the other mice suc-
cumbed to infection. Interestingly, survival did not directly corre-
late with ex vivo lymphoproliferation.
Immune recall responses in the pulmonary compartment.
Natural exposure to C. neoformans most commonly occurs fol-
lowing inhalation, and the lungs are a common site of clinical
infection with this fungus. We postulated that vaccination with
GP-cap59 would stimulate robust lung recall responses following
pulmonary challenge withC. neoformans. To test this, four groups
of mice were studied: unvaccinated uninfected, vaccinated unin-
fected, unvaccinated infected, and vaccinated infected. Lungs
were harvested 5 days after infection. Readouts were the numbers
of lung leukocytes, CD4 T cells, and CD8 T cells, as well as
cytokine skewing after ex vivo stimulation with GP-cap59. As ex-
pected, infection was associated with an influx of leukocytes into
the lung, which was more robust in the mice that had been vacci-
nated (Fig. 6A). CD4 and CD8 T cells also increased following
infection, although the absolute numbers were similar regardless
of whether the mice had been vaccinated (Fig. 6B).
Vaccination did profoundly affect the quality of the pulmonary
T cell response to infection, as assessed by intracellular cytokine
staining for the Th1, Th2, and Th17 markers gamma interferon
(IFN-), interleukin-4 (IL-4), and IL-17a, respectively. Mice that
were vaccinated and infected had a large influx of CD4 T cells
that stained positive for IFN- or IL-17a (Fig. 6C). CD4 T cells
that expressed both IFN- and IL-17a were also observed; how-
ever, there was only a slight increase in cells staining for IL-4.
Cytokine staining of CD8 T cells from the vaccinated and in-
fected mouse lungs revealed a somewhat different pattern
(Fig. 6D). First, the total number of CD8 T cells that stained for
any of the three cytokines assayedwas considerably lower. Second,
the number of CD8 T cells that stained for IL-4 was not signifi-
cantly different from the number staining for IFN- or IL-17a.
Protection against C. gattii infections. In the final set of ex-
periments, we examined whether a GP-cap59 vaccine would pro-
tect against challenge with C. gattii. An alkaline extract was made
from the C. gattii cap59 (acapsular) strain (45) and packaged into
GPs. Mice received a prime and 2 boosts of GP-cap59 and then
were challenged with 105 wild-type C. gattii strain R265 cells (46).
Controls included unvaccinated mice and mice that received GP-
MSA.Mice vaccinatedwithGP-cap59 had significantly prolonged
survival compared with the control groups (Fig. 7A). Four vacci-
nated mice survived the 70-day observation period; however, fol-
lowing euthanasia, we were able to detect C. gattii CFU in each of
those mice (Fig. 7B).
TABLE 1 LC-MS/MS analysis of protein in C. neoformans cap59 extracts
CNAG designation Description Abundancea Signal peptideb No. of RNA-Seq readsc Homologyd
CNAG_07442 Phosphatidylglycerol transfer protein 100 Yes 25,623 0.39
CNAG_01019 Superoxide dismutase [Cu-Zn] 97 No 70,771 5E62
CNAG_06432 Acetate kinase 50 No 18,367 None
CNAG_00581 Saccharopepsin 27 Yes 97,106 2E107
CNAG_01230 Chitin deacetylase 2/ MP98 24 Yes 5,835 None
CNAG_04625 Cerevisin 23 Yes 115,412 3E27
CNAG_00919 Carboxypeptidase D 19 Yes 934 6E19
CNAG_00450 3-Isopropylmalate dehydrogenase 16 No 1,129 9E30
CNAG_00734 Dihydroorotase, homodimeric type 16 No 1,814 1.5
CNAG_03232 Lactamase 14 No 23,885 3E04
CNAG_05097 YjeF family protein 13 No 8,699 1E72
CNAG_01896 Alcohol dehydrogenase (NADP) 11 No 87,413 2E71
CNAG_00264 Nuclease I 11 Yes 51,905 None
CNAG_01348 Cyanate hydratase 9 No 8,774 2.2
CNAG_04981 Catalase 7 No 101,133 2E102
CNAG_03223 Hypothetical protein 6 Yes 48,826 None
CNAG_00575 Catalase 6 No 21,202 3E81
CNAG_01498 Arylsulfatase 6 Yes 2,938 3E43
CNAG_01137 Aconitate hydratase 6 No 19,654 0
CNAG_04443 Hypothetical protein 5 No 19,418 8E10
CNAG_04269 Leucyl aminopeptidase 5 Yes 15,297 0.62
CNAG_07745 Alcohol dehydrogenase, propanol-preferring 5 No 46,734 3E12
a The relative abundance of protein, averaged for two cap59 extracts. The most abundant protein, phosphatidylglycerol transfer protein, was arbitrarily set at 100.
b Determined using SignalP 4.0.
c Average numbers of normalized RNA-Seq reads recorded for two strains of Cryptococcus isolated directly from infected human patients (GEO accession number GSE51573) (41).
d Homology to the human protein with the highest similarity (BLASTp analysis); the smaller the value, the greater the similarity.
Specht et al.
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DISCUSSION
Vaccination is one of the greatest public health successes, greatly
reducing and in some cases eliminatingmany deadly diseases (47).
Development of a vaccine to protect vulnerable people against
cryptococcosis is needed, given the prevalence of this disease and
its associated morbidity and mortality (2, 4). Here, we provide
proof of principle for a vaccination approach that packages fungal
antigens in a GP delivery system. Similar protection against a le-
thal challenge with a C. neoformans strain was observed in mice
that received subcutaneous vaccinations of GPs containing alka-
line extracts from either of two different mutant C. neoformans
strains. Similarly, an alkaline extract derived from aC. gattii strain
protected against subsequent lethal challenge with C. gattii. Pro-
tection did not appear to be due to the stimulatory effects that
-glucans have on innate and trained immunity (48, 49), as con-
trol mice that received immunizations with GPs containing only
MSA had 100% mortality.
The cryptococcal strains used to make the alkaline extracts
either lacked capsule entirely (cap59) or, in the case of the cda123
strain, the cells were loosely encapsulated (39). The lack of capsule
facilitated loading of the cap59 extracts into GPs, as the extracts
were less viscous than those from cda123. It is recognized that the
cda123 strain is deficient in three proteins that could contribute to
protection. One of the three deleted chitin deacetylases, CDA2
(also known asMP98), has been shown to be a major target of the
T cell response in mice (42, 43). For these reasons, our focus was
on the cap59 extracts.
The protection we observed was with highly virulent crypto-
coccal strains and use of a mouse strain, C57BL/6, that is highly
susceptible to cryptococcosis (35, 50). Nevertheless, while protec-
FIG 3 Survival curves following vaccination with GP-cap59 and GP-cda123. (A) Mice were left unvaccinated (No Vac) or vaccinated three times with GP-MSA,
GP-cap59, or GP-cda123. Mice were then challenged intranasally with 105 CFU of Kn99. Each experiment had five mice per group. The results with GP-cap59 and
GP-cda123 are combined from two independent experiments, one with “NoVac” and onewithGP-MSA as the control. P 0.01 comparingNoVac or GP-MSAwith
GP-cap59orGP-cda123. (B)Themice that survived50dayswere euthanizedand theCFUofKn99 in the lungsweremeasured. (C)Fivedistinct lotsofGP-cap59vaccine
were manufactured and tested as described for panel A. Each experiment had five mice per group. The cumulative results of the five studies are shown. P 0.0001
comparingGP-MSAwithGP-cap59. (D)CFUofKn99 in lungs ofmice surviving 50 days (shown in panel C). The lower limit of detection of the fungal load in the lung
was 200 CFU (B) or 20 CFU (D). Samples below detection were assigned 200 CFU (B) or 20 CFU (D). The dotted lines denote the inoculum of the challenge dose.
FIG 4 Amount of cap59 extract in GPs needed to induce an ex vivoCD4T cell
response. CD4T cells were purified from the lymph nodes and spleen ofmice
that had been vaccinated three times with GP-cap59. The cap59 extract, quan-
tified by protein concentration, was loaded in 10-fold decrements into GPs.
GPs in the “0.0” group contained MSA without cap59 extract. The T cells
(105/well) were added to wells containing 104 mitomycin C-treated BMDCs
and 105 GPs containing the indicated amount of cap59 extract. Lymphopro-
liferation was assayed by [3H]thymidine incorporation. Data are means 
standard errors of the means of results from three independent experiments,
each performed in triplicate. P 0.01 and P 0.001 comparing 0.0 versus 1.0
and 10 ng cap59 extract, respectively.
GP-Based Cryptococcal Vaccines
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tion was significant, it fell short of 100%, and sterilizing immunity
was seen in only some of the survivors. Ongoing efforts are fo-
cused on improving vaccine efficacy. This includes identifying
which of the many antigens in the alkaline extracts elicit the most
robust protection and thus should be considered for inclusion in
future subunit vaccines. The mild alkaline extraction technique
we used is predicted to remove non-covalently linked cell wall
proteins without lysing the cells. However, many of the proteins
identified in the extracts do not have signal sequences, suggesting
that the extraction procedure selectively recovers proteins located
inside the cell membrane or in extracellular vesicles (51). While
the most abundant proteins in our extracts are expressed by cryp-
tococci in infected humans (41), the possibility of additional pro-
tective antigens not found in the extracts must be entertained.
Thus, while alkaline extraction is a relatively simple technique for
generating antigens from Cryptococcus, in future candidate vac-
cines we will also test proteins identified as immunogenic (18,
52–56) and not found in abundance in the alkaline extracts.
The arm(s) of the immune system responsible for GP vaccine-
mediated protection remains to be determined. Interestingly,
when the alkaline extracts were fractioned by size exclusion chro-
matography, the fractions that stimulated the greatest CD4 lym-
phoproliferative responses were not those that afforded the great-
est protection.However, a caveat for interpretation of these results
FIG 5 Immunostimulatory and protective fractions of the cap59 extract
following size exclusion chromatography. (A) The cap59 extract was separated
on a Sephadex G-100 column. One-milliliter fractions were collected and as-
sayed for protein and carbohydrate. A 260-l portion of each fractionwas then
loaded into GPs and used as a stimulus of CD4 T cell LP (as in Fig. 4). The
shaded area indicates the pool of fractions 8 to 11 that best protected mice as a
GP vaccine. (B) Pools of four sequential fractions were loaded into GPs and
used to vaccinate mice. The fraction numbers (F#) of the pools are indicted in
shaded column. GPs loaded only with MSA served as the control GP vaccine.
Mice (5/group) were vaccinated three times and challenged with 105 CFU of
Kn99. P 0.01 comparing F#8 to 11 with MSA.
FIG 6 Analysis of leukocytes from lungs of vaccinated and/or infected mice.
In each of three studies, two mice were vaccinated with GP-cap59 three times
at 2-week intervals, and two mice were unvaccinated. Two or more weeks
following the third vaccination, a naive and a vaccinated mouse were infected
with 105 CFU of KN99 and a naive and a vaccinated mouse were not unin-
fected. Five days postinfection, the lungs were collected and single-cell suspen-
sions were prepared. (A) The leukocytes at the interface of a 67% and 40%
Percoll gradient were collected and counted. Purified leukocytes were stimu-
lated with GP-cap59 ex vivo (at a ratio of 3 GPs per 10 leukocytes) for 24 h, and
brefeldin A was added for the last 5 h of the incubation, as described in Mate-
rials andMethods. Then, the cells were collected, stained for CD3, CD4, CD8,
IFN-, IL-4, and IL-17a, and analyzed by polychromatic FACS. (B) The num-
bers of CD4 (CD3 CD4 CD8) and CD8 (CD3 CD4 CD8) T cells
were calculated by multiplying the percentage of each population times the
total leukocyte counts. (C) The numbers of CD4 T cells producing IFN-,
IL-4, IL-17a, or IFN-/IL-17a were similarly calculated. (D) As described for
panel C, the numbers of CD8 T cells producing cytokines were calculated.
Results shown are means  standard errors of the means of three indepen-
dently performed experiments with four mice for each experiment. One-way
ANOVA with Tukey multiple comparison correction was performed to com-
pare cell numbers among four groups (unvaccinated uninfected, vaccinated
uninfected, unvaccinated infected, and vaccinated infected). *, P  0.05; **,
P 0.01.
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is that the fractions were loaded into GPs based on volume rather
than protein content. Interestingly, the protective fractions had a
ratio of carbohydrate to protein characteristic of mannoproteins
(18).
Mice that were vaccinated with GP-cap59 and then challenged
with live C. neoformans responded with a robust recall T cell re-
sponse in the lung. As was observed when immunizing with GP-
OVA (23, 24), the CD4 T cell response was Th1 and Th17
skewed, as determined by cellular IFN- and IL-17a production.
In addition, a small but significant fraction of the CD4 T cells
expressed both IFN- and IL-17a. In contrast, significant num-
bers of CD4 Th2 cells, defined by IL-4 expression, were not ob-
served. In mouse models of cryptococcosis, protective responses
are strongly associated with Th1-type cytokines, with a lesser role
for Th17-type cytokines (57, 58). Th2-type cytokines are associ-
ated with exacerbation of disease.
Compared with the lung recall CD4 T cell response, the
CD8 T cell response was considerably less robust, and Tc1, Tc2,
and Tc17 cells were observed in approximately equal numbers.
This does not preclude a role for GP-based cryptococcal vaccines
in HIV-infected persons; using a live attenuated Blastomyces sp.
strain, the Klein Lab has shown that while CD8 T cells are only
weakly primed inCD4T cell-sufficient hosts, robust CD8T cell
responses occur in CD4-deficient mice (59, 60). Ongoing experi-
ments are directed at determining whether GP-based vaccines can
similarly protectmice depleted of CD4T cells. In addition, while
we hypothesize that T cells are responsible for the protection con-
ferred by our GP-based cryptococcal vaccines, the contribution of
antibodies needs to be explored.
The ideal cryptococcal vaccine should protect against both
C. neoformans and C. gattii, even in the setting of immunocom-
promise. However, in regions where C. gattii is endemic in the
environment, there may be a role for a vaccine that specifically
targets infections with this species. This may turn out to be par-
ticularly so if habitat expansion ofC. gattii continues (2, 8).While
the vast majority of persons who acquire symptomatic infection
with C. neoformans are severely immunocompromised prior to
exposure, those who acquire C. gattii infections often have no
known or only mild immunodeficiency (61). Notably, while alka-
line extracts packaged in GPs protected against both cryptococcal
species, there was a trend toward enhanced protection against
C. neoformans compared with C. gattii, despite preparing species-
specific extracts. In a related approach, Chaturvedi et al. made cell
wall and cytoplasmic protein preparations from C. gattii (62). In-
tranasal vaccination with these preparations resulted in a de-
creased fungal burden and prolonged survival following challenge
with C. gattii.
While the full translational potential of GP-based vaccines can
only be addressed with clinical studies, related -glucan-
containing preparations have been tested in humans. Notably,
-glucan preparations derived from fungi have a record of safety
in both preclinical and human trials (63–65). Moreover, heat-
killed S. cerevisiae genetically engineered to express antigens has
undergone clinical trials in immunotherapeutic vaccines (66, 67).
In phase I trials, no major toxicities, clinically significant labora-
tory abnormalities, or serious adverse events were noted, even at
the highest doses tested (66). Importantly, in both human and
animal studies, strong antigen-specific helper and cytotoxic T
lymphocyte responses were elicited (66, 68–70). Due to their
greater purity, including a lack of endogenous baker’s yeast pro-
teins, we predict GPs will be even safer than heat-killed S. cerevi-
siae.
MATERIALS AND METHODS
Chemicals and cell culture media. Chemical reagents were purchased
from Thermo, Fisher Scientific (Pittsburg, PA), unless stated otherwise.
RPMI 1640 medium was obtained from Invitrogen Life Technologies
(Carlsbad, CA). R10mediumcontainedRPMI 1640with 10% fetal bovine
serum (FBS; TissueCulture BioLogicals, Tulare, CA), 100U/ml penicillin,
100 g/ml streptomycin, 2 mM L-glutamine (Invitrogen), and 55 M
2-mercaptoethanol (Invitrogen). Incubations with mouse cells were per-
formed at 37°C in humidified air supplemented with 5% CO2.
Strains ofCryptococcus spp.Three strains ofC. neoformans var. grubii
were used in these studies: Kn99 (wild type) (71), cap59 (acapsular) (40),
and cda1 cda2 cda3 (cda123; a chitosan-deficientmutant strain) (39).
Strains of C. gattii included R265 (wild type) (46) and cap59 (acapsular,
derived from C. gattii wild-type strain NIH444) (45). R265 is the major
genotype strain from the Vancouver Island outbreak. NIH444 was origi-
nally isolated in Seattle and is identical to R265 across all 30 tested loci
(72). Each strain was maintained as a glycerol stock at 80°C and was
initially cultured on YPD agar (yeast extract [Difco], Bacto peptone [Bec-
ton, Dickinson, Sparks, MD], and dextrose [Sigma, St. Louis, MO]),
which served as inoculum for liquid cultures of YPD or YNB medium
(yeast nitrogen base [Becton, Dickinson]). To prepare Cryptococcus for in
vivo challenge studies, strains Kn99 and R265 were cultured in liquid YPD
for 18 h at 30°C with shaking. Yeast cells were then harvested by centrif-
ugation, washed once with phosphate-buffered saline (PBS), and finally
suspended in PBS.
Alkaline extraction of cryptococcal cell wall antigens. Strains of
C. neoformans were cultured in 500 ml of 2 YNB, 1% glucose from a
starting optical density at 600 nm (OD600) of 0.1. Flasks were shaken for 2
to 3 days at 30°C, followed by 1 day at 37°C. Yeast cells, typically having
reached an OD600 of 9.0 to 11.0 in that time, were collected by centrifu-
gation at 1,600  g, 22°C, for 5 min. Cells were suspended in PBS, split
between two 50-ml tubes, and then centrifuged again. The yield of 500ml
of culture was about 5 to 6 ml of packed cells in each of the 50-ml tubes;
PBS-washed cell pellets were stored at20°C. For alkaline extraction, the
cell pellets were thawed at 22°C. Cells were rapidly suspended in 1.5 vol-
FIG 7 Protection against challenge with C. gattii provided by the GP-cap59
(C. gattii) vaccine. An alkaline extract from C. gattii strain cap59 was loaded
into GPs (GP-cap59 [Cg], containing 10 g extract protein per vaccine dose).
Mice were left unvaccinated (NoVac) or vaccinated three times with GP-MSA
or GP-cap59. Mice were then inoculated intranasally with 105 CFU of C. gattii
strain R265. (A) Survival curves combined from two independent experi-
ments. The first experiment had two groups of fivemice, one of which received
GP-cap59 and the other no vaccination. The second experiment had two
groups. One group contained nine mice which received GP-cap59. The other
group had five mice which received GP-MSA. P  0.0001 comparing GP-
cap59 with either control group. (B) C. gattii CFU in the lung of each mouse
(n  4) that survived 70 days. The dotted line denotes the inoculum of the
challenge dose.
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umes of 0.1 M potassium hydroxide (KOH) and rotated for 10 min at
22°C, then removed by centrifugation, as described above. For each mil-
liliter of supernatant, 25 l 1 M sodium acetate buffer, pH 4.5, was added
to neutralize the KOH, followed by mixing with 1.5 volumes of isopropa-
nol and storage at20°C overnight. The precipitate was collected follow-
ing centrifugation at 6,000 g for 10 min at 4°C, suspended in 15 ml 0.1
M ammonium acetate, then reprecipitatedwith 2 volumes of ethanol, and
kept overnight at20°C. Centrifugationwas repeated, and the precipitate
was dried by lyophilization. It was then suspended in 7.5 ml 0.01 M am-
monium acetate and clarified by centrifugation at 6,000 g for 10 min at
4°C. The supernatant containing soluble alkaline extracted antigens was
saved and stored at80°C. The protein concentration was measured in a
bicinchoninic acid (BCA) assay, and carbohydrate was determined by the
phenol-sulfuric acid method of Dubois (73). Endotoxin levels of the ex-
tracts were measured using the Limulus amebocyte lysate (LAL) pyro-
chrome reagent in Glucashield buffer according to the manufacturer’s
instructions (Associates of Cape Cod, Falmouth, MA). SDS-PAGE was
used to separate antigens in extracts. Gels were stained with either Coo-
massie stain (RapidStain; G-Biosciences, St. Louis, MO) for protein or
PAS (Schiff’s reagent; Electron Microscopy Sciences, Hatfield, PA) for
carbohydrates.
Analysis of cap59 extracts by electrospray ionization LC-MS/MS.
Samples were processed for analysis by LC-MS/MS as previously de-
scribed (74). Briefly, for each sample, 50 g protein was electrophoresed
into a 10% Mini-Protean Tris-glycine extended (TGX)-PAGE gel (Bio-
Rad Laboratories) in Tris-glycine–SDS buffer, stained with Coomassie,
destained with water, and removed as a gel slice. Gel slices were cut into 1-
by 1-mmpieces, reduced in a 45mM solution of 1,4-dithiothreitol (DTT)
at 50°C for 30 min, alkylated in 100 mM iodoacetamide for 30 min, and
digested with 2 ng/l of sequencing-grade trypsin (Sigma) in 0.01% Pro-
teaseMAX surfactant (Promega)–50mMammoniumbicarbonate at 37°C
for 18 h. The supernatant of each sample was then placed in a 0.5-ml
microcentrifuge tube. The gel slices were further extracted with 80:20
acetonitrile–1% formic acid, combined with the supernatants of each
sample, and completely dried in a SpeedVac.
Tryptic peptide digests were reconstituted in 25 l 5% acetonitrile
containing 0.1% (vol/vol) trifluoroacetic acid and separated using a
NanoAcquity ultraperfomance liquid chromatography system (Waters
Corporation, Milford, MA). In brief, a 3.0-l injection was loaded in 5%
acetonitrile containing 0.1% formic acid at 4.0 l/min for 4.0 min onto a
100-m-inner-diameter (i.d.) fused-silica precolumn packed with 2 cm
of 5-m (200-Å) Magic C18AQ resin (Bruker-Michrom, Auburn, CA)
and eluted using a gradient at 300 nl/min onto a 75-m-i.d. analytical
column packed with 25 cm of 3-m (100-Å) Magic C18AQ particles to a
gravity-pulled tip. The solvents were A (water–0.1% formic acid) and B
(acetonitrile–0.1% formic acid). A linear gradient was developed from
5% solvent A to 35% solvent B in 60min. Ionswere introduced by positive
electrospray ionization via liquid junction into a Q Exactive hybrid mass
spectrometer (Thermo Scientific). Mass spectra were acquired over m/z
300 to 1750 at 70,000 resolution (m/z 200), and data-dependent acquisi-
tion selected the 10 most abundant precursor ions for tandemmass spec-
trometry by higher-energy collisional dissociation fragmentation using an
isolation width of 1.6 Da, collision energy of 27, and a resolution of
17,500.
Raw data files were peak processedwith ProteomeDiscoverer (version
1.3; Thermo Scientific) or Mascot Distiller (version 2.4; Matrix Science,
Inc., Boston, MA) prior to database searching with the Mascot server
(version 2.4) against the C. neoformans var. grubii database (National
Center for Biotechnology Information). Search parameters included both
trypsin specificity with twomissed cleavages and no enzymatic specificity.
The variablemodifications of oxidizedmethionine, pyroglutamic acid for
N-terminal glutamine, deamidation of aspargine and glutamine,
N-terminal acetylation of the protein, and a fixed modification for carb-
amidomethyl cysteine were considered. Themass tolerances were 10 ppm
for the precursor and 0.05 Da for the fragments. Search results were then
loaded into the Scaffold viewer (Proteome Software, Inc., Portland, OR)
for peptide/protein validation. MS data were analyzed with Mascot soft-
ware using two search criteria: a conventional search based on tryptic
digestion sites and an expanded search in which no digestion enzyme was
specified. Proteins were identified with Scaffold software (Proteome Soft-
ware, Inc.), and probabilities were assigned by using the Protein Prophet
algorithm; identifications were accepted if they could be established at
	95% probability for at least two peptides. The Mascot Distiller average
quantitation method was used, in which the precursor intensities of the
three most abundant peptides are used to compute a protein’s relative
abundance in a sample.
GP vaccines. Saccharomyces cerevisiae cells were converted into GPs
following a series of hot alkali, organic, and aqueous extraction steps, as
described previously (23, 24, 27, 31). The final product consisted of a
highly purified 3- to 4-m-diameter yeast cell wall preparation devoid of
cytoplasmic content and bounded by a porous, insoluble shell of
-glucans. The final GP vaccine consisted ofCryptococcus alkaline extract,
mouse serum albumin (Equitech-Bio, Kerrville, TX), and yeast RNA
(yRNA; Sigma) complexed within the glucan shells. Samples to be loaded
into GPs were concentrated by lyophilization and dissolved in water at 5
to 10mg/ml by protein content. Antigens were loaded into GPs and com-
plexed with MSA and yRNA as described elsewhere (23, 24, 27). Vaccines
were diluted in sterile 0.9% saline for injection to deliver the indicated
amount (ranging from 0.01 to 10 g) of antigen in 200-g GPs (approx-
imately 108 particles) per 0.1-ml dose. A control vaccine consisted of GPs
loaded with MSA and yRNA but without cryptococcal alkaline extract.
Vaccines were stored in 0.6-ml aliquots at 80°C and briefly vortexed
prior to use. Vaccine formulations were quality controlled by manual
counting of the number of GPs per milliliter by using a hematocytometer
andmicroscopically assessing for intactGPswith a phase-distinct protein-
yRNA complex. Vaccines were also extracted and analyzed by 10% SDS-
PAGE to quantify antigen/MSA loading.
GPantigen fractionvaccines.Cryptococcus extractswere size fraction-
ated by Sephadex G-100 gel filtration. One milligram (based on protein
content) in 0.5 ml of 0.1M ammonium acetate, 20 mMTris-HCl, pH 7.4,
was separated on a 1.5- by 7.0-cm column equilibrated with the same
buffer as the sample. One-milliliter fractions were collected and analyzed
for protein and carbohydrate. A 260-l portion from each fraction was
lyophilized and suspended in 26 l water, and then 5-l aliquots of each
10 concentrated fraction were loaded into 1-mg GPs and complexed
with MSA and yRNA, as described above. The loaded GPs were each
suspended in 0.5 ml 0.9% saline and frozen for later use as stimuli for LP
assays. The fractions were also tested in GP-based vaccines. Pools of four
sequential fractions containing 0.6 ml of one fraction were lyophilized,
suspended in 20 l of water, and loaded into 4-mg GPs, as described
above. Vaccines were diluted to 2 mg/ml in sterile 0.9% saline for injec-
tion. Aliquots containing 0.6 ml of vaccine were frozen until use in vacci-
nation studies.
Mice. Six-week-old female C57BL/6 mice were obtained from either
Charles River Laboratories (Kingston, NY) or The Jackson Laboratory
(Bar Harbor, ME). Mice were housed in a pathogen-free environment in
the animal facility at the University of Massachusetts Medical School, All
animal procedures were carried out under a protocol approved by the
University ofMassachusettsMedical School Institutional Use and Care of
Animals Committee.
Vaccination and challenge studies. The GP-based vaccines and the
live Cryptococcus vaccines (0.1 ml dose) were administered three times at
2-week intervals as a subcutaneous injection at the midline of the abdo-
men, as described elsewhere (23, 24). Two weeks after the third vaccina-
tion, the mice were challenged withC. neoformans strain Kn99 orC. gattii
strain R265. Mice were anesthetized with 2% isoflurane (Piramal Health
Care, Andrah Pradesh, India) in a laboratory animal anesthesia system
(VetEquip, Livermore, CA) and inoculated intranasally with 50l of fun-
gal suspension, so as to deliver 103, 104, or 105 CFU of Cryptococcus. For
survival studies, mice were monitored twice daily and euthanized if they
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developed advanced signs of disease, including ataxia, listlessness, and
failure to groom. At the termination of the study, surviving mice were
euthanized, and lungs were removed and homogenized in 4 ml PBS con-
taining penicillin and streptomycin. Undiluted and diluted homogenates
were plated on Sabouraud dextrose agar, Emmons, and incubated at 30°C
for 2 to 3 days, at which time CFU of Cryptococcus were enumerated. For
other studies, mice were sacrificed 2weeks after fungal challenge, at which
time lung and brain CFU were counted.
Lymphoproliferation. An LP assay was performed essentially as de-
scribed elsewhere (23, 24). Briefly, 2 or more weeks after the third vacci-
nation, mice were euthanized and spleens and inguinal lymph nodes were
collected. Single-cell suspensions were prepared, and CD4 T cells were
isolated over magnetic bead columns by negative selection according to
the manufacturer’s protocol (Miltenyi Biotec, San Diego, CA). Purified
CD4 T cells (105/well) were incubated with the indicated stimuli in
round-bottom 96-well plates containing 200l R10medium.Mitomycin
C-treated murine bone marrow-derived dendritic cells (BMDCs; 104/
well, generated as described elsewhere [23]) served as antigen-presenting
cells. After a 3-day incubation, [3H]thymidine (1 Ci/well; PerkinElmer,
Boston, MA) was added, and the plates were incubated for an additional
24 h. Cells were then collected on filter paper (Wallac, Turku, Finland) by
using a harvester (Brandel, Gaithersburg, MD), and [3H]thymidine in-
corporation was measured with a beta counter (1450MicroBeta;Wallac).
Each condition was analyzed in triplicate.
Polychromatic fluorescence-activated flow cytometry.
Fluorescence-activated cell sorting (FACS) flow cytometrywas performed
as previously described with slight modifications (24). Briefly, single-cell
suspensions were prepared frommouse lungs by using a lung dissociation
kit (Miltenyi Biotec) according to the manufacturer’s protocol. The cell
pellets were resuspended in 40% Percoll in PBS, layered on top of 67%
Percoll in RPMI, and centrifuged at 600 g for 20 min. The lung leuko-
cytes at the interface were collected andwashed twice with PBS. Cells were
then counted on a hemocytometer and incubatedwith the indicated stim-
uli for 24 to 28 h. Brefeldin A (10 g/ml) was added for the last 5 h of
incubation. Following incubation with Fc-blocking antibodies (BD Bio-
sciences, San Jose, CA), the cells were stained for surface antigens (CD3
conjugated to fluorescein isothiocyanate, CD4 conjugated to V500), and
CD8 conjufated to V450) and intracellular cytokines IFN- (Alexa 700
conjugate), IL-4 (allophycocyanin conjugate), and IL-17A (phycoerythin
conjugate) after fixation and permeabilization using the Cytofix/Cy-
toperm fixation/permeabilization solution kit (BD Biosciences). Single-
color controls for CD3, CD4, CD8, IFN-, IL-4, and IL-17A were pre-
pared using OneComp ebeads according to the manufacturer’s protocol
(eBiosciences). FACS data were collected using an LSR II flow cytometer
(BDBiosciences) and analyzed using FlowJo software (Tree Star, Ashland,
OR). Briefly, singlets were selected while debris and SSChi cells were re-
moved. Then, the CD4 CD8 and CD4 CD8 cell populations were
selected from the CD3 population. Finally, the expression levels of
IFN-, IL-4, and IL-17A on the CD3 CD4 CD8 and CD3 CD4
CD8 gated populations were examined.
Statistics. Data were analyzed using GraphPad Prism, version 6.0
(GraphPad Software, La Jolla, CA). Kaplan-Meier survival curves were
analyzed for significance using the log rank test. For the ex vivo experi-
ments, comparisons were made using a one-way analysis of variance
(ANOVA) with the Tukey multiple correction.
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